Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Furthermore, significant difference were observed in history of osteoporosis/brittle bones, levels of HbA1c, FPG, serum INS, HOMA-IR, sCr, UA, TBL and 25(OH)D among the three groups.Weighted characteristics of US adults ≥ 50 years old with NGR, prediabetes and diabetes, 1999 to 2002NGR (n = 1939)Prediabetes (n = 1172)Diabetes (n = 891)PAge (years)61.81 ± 9.7164.43 ± 10.1864.70 ± 9.49< 0.001Male (%)44.350.550.00.019Race/Ethnicity Non-Hispanic white (%)85.175.165.3< 0.001 Non-Hispanic black (%)5.59.215.9 Mexican American (%)2.93.85.6 Other races (%)6.511.913.2Educational level Under high school (%)20.428.440.9< 0.001 High school or equivalent (%)25.026.825.2 Above high school (%)54.644.833.9Marital status Married/living with partner (%)71.370.061.40.015 Widowed/divorced/separated (%)25.626.432.6 Never married (%)3.13.66.0PIR ≤ 1 (%)8.712.017.4< 0.001 1 < to ≤ 3 (%)31.039.645.1 > 3 (%)60.348.437.5Smoked ≥ 100 cigarettes in life (%)55.054.854.90.993Vigorous activities (%)30.218.219.4< 0.001Sedentary activities < 1 h/day11.611.18.9< 0.001 1 to 3 h/day64.357.555.2 ≥ 3 h/day24.131.435.9Cancer (%)14.315.416.60.442Osteoporosis or brittle bones (%)9.36.210.00.015SBP (mmHg)133.62 ± 21.70138.83 ± 22.40137.70 ± 22.31< 0.001DBP (mmHg)74.21 ± 13.0072.97 ± 15.6269.52 ± 16.29< 0.001HbA1c (%)5.27 ± 0.245.70 ± 0.327.47 ± 1.81< 0.001FPG (mmol/L)4.92 ± 0.365.58 ± 0.578.44 ± 4.00< 0.001INS (µU/mL)8.51 ± 4.8912.89 ± 8.4024.50 ± 32.60< 0.001HOMA-IR2.21 ± 1.303.86 ± 2.6511.27 ± 12.93< 0.001TBL (µmol/L)11.58 ± 5.0711.08 ± 4.6410.71 ± 4.25< 0.001sCr (µmol/L)75.97 ± 44.1377.51 ± 29.9185.66 ± 71.25< 0.001UA (µmol/L)320.23 ± 86.82352.87 ± 85.12339.82 ± 96.13< 0.001TC (mmol/L)5.46 ± 0.995.50 ± 1.035.23 ± 1.20< 0.001Serum 25(OH)D (nmol/L)63.73 ± 20.5659.71 ± 20.2055.55 ± 18.85< 0.001Mean ± SD for continuous variables; proportion for categorical variablesNGR normal glucose regulation, PIR ratio of family income to poverty, SBP systolic blood pressure, DBP diastolic blood pressure, HbA1c hemoglobin A1c, FPG fasting plasma glucose, TBL total bilirubin, sCr serum creatinine, UA uric acid, TC total cholesterol, 25(OH)D 25-hydroxyvitamin D

Source: Characteristics of the participants across the two survey cycles. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

A total of 4002 participants aged ≥ 50 years with available information on glucose status (NGR: 1939 cases; prediabetes: 1172 cases; diabetes: 891 cases) and sarcopenia were included in this study.

Source: Abstract.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Prediabetes and diabetes were attributed to the prevalence and severity of sarcopenia in middle-aged and elderly adults

Study design awaiting verification · Diabetology & Metabolic Syndrome · 2024

Original publication title

Prediabetes and diabetes were attributed to the prevalence and severity of sarcopenia in middle-aged and elderly adults

Jing Yuan; Pu Jia

© The Author(s) 2024

Original publication · Publisher record · CC BY 4.0 · CC0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Prediabetes and diabetes were independently associated with the prevalence and severity of sarcopenia in US population. Slowing down the progression of hyperglycemia could have prevented a significant proportion of sarcopenia cases.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Sarcopenia and diabetes are both prevalent health problems worldwide. However, little is known about the relationship between prediabetes and the prevalence and severity of sarcopenia. Therefore, the current study aimed to explore the association between glucose status and the components of sarcopenia, including low muscle mass (LMM), low muscle strength (LMS) and low gait speed (LGS) in US adults.

Source: Background

Abstract: What methods does the paper describe?

Data from the 1999 to 2002 National Health and Nutrition Examination Survey (NHANES) were analyzed. A total of 4002 participants aged ≥ 50 years with available information on glucose status (NGR: 1939 cases; prediabetes: 1172 cases; diabetes: 891 cases) and sarcopenia were included in this study. Sarcopenia was defined according to the Foundation for National Institute of Health criteria. Muscle mass, muscle strength and gait speed were used to evaluate sarcopenia and its severity. Weighed multivariable logistic regression were used to explore the association between glucose status and the components of sarcopenia.

The hypothetical population attributable fraction (PAF) for the glucose status was also calculated.

Source: Methods

Abstract: Results

The mean age of the cohort was 63.01 ± 9.89 years, with 49.4% being male. Multiple logistic regression analysis suggested that diabetes was an independent risk factor for sarcopenia (OR = 5.470, 95% CI 1.551 to 19.296) and showed a marginal association with severe sarcopenia (OR = 10.693, 95% CI 0.955 to 119.73) compared to NGR in men, but not in women. Additionally, prediabetes was independently associated with severe sarcopenia (OR = 3.647, 95% CI 1.532 to 8.697), LMS (OR = 1.472, 95% CI 1.018 to 2.127) and LGS (OR = 1.673, 95% CI 1.054 to 2.655) in the entire cohort.

When stratifying by gender, we further observed that prediabetes was significantly associated with LMS in men (OR = 1.897, 95% CI 1.019 to 3.543) and related to LMM (OR = 3.174, 95% CI 1.287 to 7.829) and LGS (OR = 2.075, 95% CI 1.155 to 3.727) in women. HbA1c was positively associated with the prevalence of sarcopenia in men (OR = 1.993, 95% CI 1.511 to 2.629). PAF showed that diabetes accounted for 16.3% of observed sarcopenia cases. Maintaining NGR in the entire population could have prevented 38.5% of sarcopenia cases and 50.9% of severe sarcopenia cases.

Source: Results

Abstract: Conclusions

Prediabetes and diabetes were independently associated with the prevalence and severity of sarcopenia in US population. Slowing down the progression of hyperglycemia could have prevented a significant proportion of sarcopenia cases.

Source: Conclusions
Authors’ abstract

Background

Sarcopenia and diabetes are both prevalent health problems worldwide. However, little is known about the relationship between prediabetes and the prevalence and severity of sarcopenia. Therefore, the current study aimed to explore the association between glucose status and the components of sarcopenia, including low muscle mass (LMM), low muscle strength (LMS) and low gait speed (LGS) in US adults.

Methods

Data from the 1999 to 2002 National Health and Nutrition Examination Survey (NHANES) were analyzed. A total of 4002 participants aged ≥ 50 years with available information on glucose status (NGR: 1939 cases; prediabetes: 1172 cases; diabetes: 891 cases) and sarcopenia were included in this study. Sarcopenia was defined according to the Foundation for National Institute of Health criteria. Muscle mass, muscle strength and gait speed were used to evaluate sarcopenia and its severity. Weighed multivariable logistic regression were used to explore the association between glucose status and the components of sarcopenia.

The hypothetical population attributable fraction (PAF) for the glucose status was also calculated.

Results

The mean age of the cohort was 63.01 ± 9.89 years, with 49.4% being male. Multiple logistic regression analysis suggested that diabetes was an independent risk factor for sarcopenia (OR = 5.470, 95% CI 1.551 to 19.296) and showed a marginal association with severe sarcopenia (OR = 10.693, 95% CI 0.955 to 119.73) compared to NGR in men, but not in women. Additionally, prediabetes was independently associated with severe sarcopenia (OR = 3.647, 95% CI 1.532 to 8.697), LMS (OR = 1.472, 95% CI 1.018 to 2.127) and LGS (OR = 1.673, 95% CI 1.054 to 2.655) in the entire cohort.

When stratifying by gender, we further observed that prediabetes was significantly associated with LMS in men (OR = 1.897, 95% CI 1.019 to 3.543) and related to LMM (OR = 3.174, 95% CI 1.287 to 7.829) and LGS (OR = 2.075, 95% CI 1.155 to 3.727) in women. HbA1c was positively associated with the prevalence of sarcopenia in men (OR = 1.993, 95% CI 1.511 to 2.629). PAF showed that diabetes accounted for 16.3% of observed sarcopenia cases. Maintaining NGR in the entire population could have prevented 38.5% of sarcopenia cases and 50.9% of severe sarcopenia cases.

Conclusions

Prediabetes and diabetes were independently associated with the prevalence and severity of sarcopenia in US population. Slowing down the progression of hyperglycemia could have prevented a significant proportion of sarcopenia cases.

Supplementary Information

The online version contains supplementary material available at 10.1186/s13098-024-01355-3.

Publication and source details

Original title: Prediabetes and diabetes were attributed to the prevalence and severity of sarcopenia in middle-aged and elderly adults

Jing Yuan; Pu Jia

Diabetology & Metabolic Syndrome · 2024

© The Author(s) 2024https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T11:09:38.343851+00:00

DOI: 10.1186/s13098-024-01355-3 · PMC11145839